Download Nieuwe antikankergenees middelen die de huid treffen

NEDERLANDS TIJDSCHRIFT VOOR DERMATOLOGIE EN VENEREOLOGIE | VOLUME 23 | NUMMER 04 | April 2013
Nieuwe antikankergenees­
middelen die de huid treffen
S. Segaert
Literatuur
1. Johnston JB, et al. Targeting the EGFR pathway for cancer
therapy. Curr Med Chem 2006;13:3483-92.
2. Segaert S, Cutsem E Van. Clinical signs, pathophysiology
and management of skin toxicity during therapy with
epidermal growth factor receptor inhibitors. Ann Oncol
2005;16:1425-33.
3. Busam KJ, et al. Cutaneous side-effects in cancer patients
treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76.
4. Robert C, et al. Cutaneous side-effects of kinase inhibitors
and blocking antibodies. Lancet Oncol 2005;6:491-500.
5. Galimont-Collen AFS, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal
growth factor receptor (EGFR) inhibitors. Eur J Cancer
2007;43:845-51.
6. Melichar B, Nemcova I. Eye complications of cetuximab
therapy. Eur J Cancer Care 2007;5:439-43.
7. Lacouture ME. Mechanisms of cutaneous toxicities to
EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
8. Ocvirk J, Rebersek M. Management of cutaneous side effects
of cetuximab therapy with vitamin K1 cream. Radiol Oncol
2008;42:215-24.
9. Segaert S, et al. The management of skin reactions in cancer
patients receiving epidermal growth factor receptor targeted
therapies.
J Dtsch Dermatol Ges 2005;3:599-606.
10. Segaert S, Cutsem E Van. Clinical management of EGFRI
dermatologic toxicities: the European perspective. Oncology
2007;11Suppl5:22-6.
11. Perez-Soler R, et al. HER1/EGFR inhibitor-associated rash:
future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management
forum. Oncologist 2005;10:345-56.
12. Lynch TJ, et al. Epidermal growth factor receptor inhibitorassociated cutaneous toxicities: an evolving paradigm in
clinical management. Oncologist 2007;12:610-21.
13. Scope A, et al. A prospective randomized trial of topical
pimecrolimus for cetuximab-associated acnelike eruption. J
Am Acad Dermatol 2009;61:614-20.
14. Scope A, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption. J Clin Oncol 2007;25:5390-6.
15. Jatoi et al. Tetracycline to prevent epidermal growth factor
receptor-induced skin rashes. Results of a placebo-controlled
trial of the North Central Cancer Treatment Group. Cancer
2008;113:847-53.
16. Lacouture ME, et al. Skin toxicity evaluation protocol with
panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin
treatment regimen on skin toxicities and quality of life in
patients with metastatic colorectal cancer. J Clin Oncol
2010;28:1351-7.
17. Luu M, et al. Photosensitive rash due to the epidermal
growth factor receptor inhibitor erlotinib. Photodermatol
Photoimmunol Photomed 2007;23:42‑5.
18. Segaert S: Management of skin toxicity of epidermal growth
factor receptor inhibitors. Targ Oncol 2008;3:245-51.
19. Heidary N, et al. Chemotherapeutic agents and the skin: an
update. J Am Acad Dermatol 2008;58:545-70.
20.Lacouture ME, et al. Hand-foot skin reaction in cancer
patients treated with the multikinase inhibitors sorafenib
and sunitinib. Ann Oncol 2008;19:1955-61.
21. Yang CH, et al. Hand-foot skin reaction in patients treated
with sorafenib: a clinicopathological study of cutaneous
manifestations due to multitargeted kinase inhibitor therapy.
Br J Dermatol 2008;158:592-6.
22. Robert C, et al. Dermatologic symptoms associated with
the multikinase-inhibitor sorafenib. J Am Acad Dermatol
2009;60:299-305.
23. Lacouture ME, et al. Evolving strategies for the management
of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist
2008;13:1001-11.
24. Valeyrie L, et al. Adverse cutaneous reactions to imatinib
(STI571) in Philadelphia chromosome-positive leukemias:
a prospective study of 54 patients. J Am Acad Dermatol
2003;48:201-6.
25. Sankhala K, et al. The emerging safety profile of mTOR
inhibitors, a novel class of anticancer agents. Targ Oncology
2009;4:135-142.
26.Mahe E, et al. Cutaneous adverse events in renal transplant
recipients receiving sirolimus-based therapy. Transplantation
2005;79:476-482.
27. Mahe E, et al. Acne in recipients of renal transplantation
treated with sirolimus: Clinical, microbiologic, histologic,
therapeutic, and pathogenic aspects. J Am Acad Dermatol
2006;55:139-142.
28.Kunzle N, et al. Sirolimus-induced acneiform eruption.
Dermatology 2005;211:366-9.
29.Raymond E, et al. Safety and pharmacokinetics of escalated
doses of weekly intravenous infusions of CCI-779, a novel
mTOR inhibitor, in patients with cancer. J Clin Oncol
2004;22:2336-47.
30.O’Donnell A, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid
tumors. J Clin Oncol 2008;26:1588-95.
31. Mita MM, et al. Phase I trial of the novel mammalian
target of rapamycin inhibitor deforolimus (AP23573;
MK-8669) administered intravenously daily for 5 days every
2 weeks to patients with advanced malignancies. J Clin
Oncol 2008;26:361-7.